Amlodipine drug therapeutic failure: a rare case report

Kandarp K. Thakkar, Kartik Shah, Devang Rana, Supriya D. Malhotra, Pankaj R. Patel


Drug Therapeutic failure is a rare condition which is underreported in recent scenario. It is important for the chronic diseases like Hypertension where it could lead to fatal outcome. In our case report elderly male patient taking tablet Amlodipine once daily as antihypertensive medication and had 2 years without any events. Patient came to the emergency department with the complaint of altered sensorium and elevated blood pressure. The mechanism for sudden increase in blood pressure (Decreased Therapeutic Response) in patient with ongoing treatment with amlodipine could be due to sympathetic over activity (e.g. stress), pharmacokinetic variation or counterfeit drug.


Amlodipine, Drug therapeutic failure, Hypertension, Pharmacovigilance

Full Text:



World Health Organization Expert Committee. WHO model list of essential medicines: 12th list. Geneva: WHO, April 2002. Available at: medicines/organization/par/edl/edl2002core.pdf

Figueras A, Laporte JR. Failures of the therapeutic chain as a cause of drug ineffectiveness: Promotion, misinformation, and economics work better than needs. BMJ: British Medical J. 2003;326(7395):895-6.

James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-20.

Toupance O, Lavaud S, Canivet E. Antihypertensive effect of amlodipine and lack of interference with cyclosporine metabolism in renal transplant recipients. Hypertension. 1994 Sep;24:297-300.

Naidu MUR, Usha PR, Rao TRK. Evaluation of amlodipine, lisinopril, and a combination in the treatment of essential hypertension Postgraduate Medical J. 2000;76:350-3.

Amlodipine besylate and Therapeutic response decreased - from FDA reports. Available at: (accessed on 01 February 2017 & 13 July 2017).

Dominiczak AF, Negrin DC, Clark JS, Brosnan MJ, mcbride MW, Alexander MY. Genes and hypertension: from gene mapping in experimental models to vascular gene transfer strategies. Hypertension. 2000;35:164-72.

Franceschi A, Tuccori M, Bocci G, Vannozzi F, Di Paolo A, Barbara C, et al. Drug therapeutic failures in emergency department patients. A university hospital experience. Pharmacol Res. 2004;49:85-91.

Bochud CB, Elston M, Bovet RC, Maillard P, Nussberger NP, Schild J, et al. CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt. / Eap, In: Hypertension. 2007;49(5):1007-14.

Guo, Chengxian. Effects of Genetic Factors on the Pharmacokinetics and Pharmacodynamics of Amlodipine in Primary Hypertensive Patients. Biomedical Reports. 2015;3(2):195-200. PMC. Web. 19 July 2017.

Koga Y, Hirooka Y, Araki S, Nozoe M, Kishi T, Sunagawa K. High salt intake enhances blood pressure increase during development of hypertension via oxidative stress in rostral ventrolateral medulla of spontaneously hypertensive rats. Hypertension Research. 2008 Nov 1;31(11):2075-83.

Rafey MA. Resistant hypertension in the elderly. Clinics in Geriatric Medicine. 2009;25(2):289-301.

Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy vs. monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290-300.

Mancia G, Fagard R, Narkiewicz K. ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219.